Please login to the form below

Not currently logged in
Email:
Password:

BioCryst

This page shows the latest BioCryst news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

CHMP round-up. At its meeting last week, the CHMP also backed approval of Ammtek’s Amiglidia (glibenclamide) as the first-ever medicine to treat neonatal diabetes and Biocryst’s Alpivir

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).

  • Pharma deals during October 2012 Pharma deals during October 2012

    150. Covagen / Mitsubishi. Collaboration &licence. Tanabe Fynomer-antibody platform for bispecific proteins (FynomAbs)  . 145+. Presidio / BioCryst. Acquisition. Hepatitis C portfolio (lead product phase I/II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics